Connective tissue nevus misdiagnosed as juvenile localized scleroderma.
Connective tissue nevus
Hamartoma
Juvenile scleroderma
Morphea
Pediatric dermatology
Scleroderma
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
received:
20
06
2023
accepted:
12
10
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
Connective tissue nevi (CTN) are congenital hamartomas caused by excessive proliferation of dermis components. In children, CTN can mimic juvenile localized scleroderma (JLS), an immune mediated skin disorder that requires aggressive immunosuppression. Aim of our study was to describe a series of pediatric patients with CTN misdiagnosed as JLS and the discerning characteristics between the two conditions. Retrospective analysis of children referred to our Center during the last two decades for JLS who received a final diagnosis of CTN. Clinical, laboratory, histopathological and instrumental data (MRI and thermography) were collected and compared with those with JLS. Seventeen patients with mean age at onset 4.6 years entered the study. All came to our Center with a certain diagnosis of JLS (n = 15) or suspected JLS (n = 2). The indurated skin lesions were flat and resembled either circumscribed morphea or pansclerotic morphea. In 14 patients (82.4%) they were mainly localized at the lower limbs and in three (17.6%) at the upper limbs. No patient had laboratory inflammatory changes or positive autoantibodies. Skin biopsies confirmed the diagnosis of CTN: non-familial collagenoma in eleven (64.7%), mixed CTN in four (23.5%) and familial CTN in two (11.8%). Mean age at final diagnosis was 9.5 years, with a mean diagnostic delay of 4.8 years (range 1-15 years). Sixteen patients underwent musculoskeletal MRI that was normal in all except two who showed muscle perifascial enhancement. Thermography was normal in all patients. At our first evaluation, eleven patients (64.7%) were on systemic treatment (methotrexate 11, corticosteroids 7, biologics 2), three (17.6%) on topical corticosteroids and three untreated. CTN can be misdiagnosed as JLS and therefore aggressively treated with prolonged and inappropriate immunosuppression. The absence of inflammatory appearance of the skin lesions, normal instrumental and laboratory findings and the accurate evaluation of skin biopsy are crucial to address the right diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Connective tissue nevi (CTN) are congenital hamartomas caused by excessive proliferation of dermis components. In children, CTN can mimic juvenile localized scleroderma (JLS), an immune mediated skin disorder that requires aggressive immunosuppression.
OBJECTIVES
OBJECTIVE
Aim of our study was to describe a series of pediatric patients with CTN misdiagnosed as JLS and the discerning characteristics between the two conditions.
METHODS
METHODS
Retrospective analysis of children referred to our Center during the last two decades for JLS who received a final diagnosis of CTN. Clinical, laboratory, histopathological and instrumental data (MRI and thermography) were collected and compared with those with JLS.
RESULTS
RESULTS
Seventeen patients with mean age at onset 4.6 years entered the study. All came to our Center with a certain diagnosis of JLS (n = 15) or suspected JLS (n = 2). The indurated skin lesions were flat and resembled either circumscribed morphea or pansclerotic morphea. In 14 patients (82.4%) they were mainly localized at the lower limbs and in three (17.6%) at the upper limbs. No patient had laboratory inflammatory changes or positive autoantibodies. Skin biopsies confirmed the diagnosis of CTN: non-familial collagenoma in eleven (64.7%), mixed CTN in four (23.5%) and familial CTN in two (11.8%). Mean age at final diagnosis was 9.5 years, with a mean diagnostic delay of 4.8 years (range 1-15 years). Sixteen patients underwent musculoskeletal MRI that was normal in all except two who showed muscle perifascial enhancement. Thermography was normal in all patients. At our first evaluation, eleven patients (64.7%) were on systemic treatment (methotrexate 11, corticosteroids 7, biologics 2), three (17.6%) on topical corticosteroids and three untreated.
CONCLUSIONS
CONCLUSIONS
CTN can be misdiagnosed as JLS and therefore aggressively treated with prolonged and inappropriate immunosuppression. The absence of inflammatory appearance of the skin lesions, normal instrumental and laboratory findings and the accurate evaluation of skin biopsy are crucial to address the right diagnosis.
Identifiants
pubmed: 37848914
doi: 10.1186/s12969-023-00913-9
pii: 10.1186/s12969-023-00913-9
pmc: PMC10583392
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Uitto J, Santa Cruz DJ, Eisen AZ. Connective tissue nevi of the skin. Clinical, genetic, and histopathologic classification of hamartomas of the collagen, elastin, and proteoglycan type. J Am Acad Dermatol. 1980;3(5):441–61. PMID: 7217375.
doi: 10.1016/S0190-9622(80)80106-X
Pierard GE, Lapiere CM. Nevi of connective tissue: a reappraisal of their classification. Am J Dermatopathol. 1985;7:325–33.
doi: 10.1097/00000372-198508000-00003
Saussine A, Marrou K, Delanoé P, et al. Connective tissue nevi: an entity revisited. J Am Acad Dermatol. 2012;67(2):233–9. https://doi.org/10.1016/j.jaad.2011.08.008 . Epub 2011 Oct 19. PMID: 22014540.
doi: 10.1016/j.jaad.2011.08.008
McCuaig CC, Vera C, Kokta V, et al. Connective tissue nevi in children: institutional experience and review. J Am Acad Dermatol. 2012;67(5):890–7. https://doi.org/10.1016/j.jaad.2012.01.036 . Epub 2012 Jun 26. PMID: 22739355.
doi: 10.1016/j.jaad.2012.01.036
Pope V, Dupuis L, Kannu P, et al. Buschke-Ollendorff syndrome: a novel case series and systematic review. Br J Dermatol. 2016;174(4):723–9. https://doi.org/10.1111/bjd.14366 . Epub 2016 Mar 8. PMID: 26708699.
doi: 10.1111/bjd.14366
Arora H, Falto-Aizpurua L, Cortés-Fernandez A, et al. Connective tissue nevi: a review of the literature. Am J Dermatopathol. 2017;39(5):325–41. https://doi.org/10.1097/DAD.0000000000000638 . PMID: 28426484.
doi: 10.1097/DAD.0000000000000638
Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13. https://doi.org/10.1097/01.bor.0000245727.40630.c3 . PMID: 17053506.
doi: 10.1097/01.bor.0000245727.40630.c3
Zulian F, Athreya BH, Laxer RM, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614–20. https://doi.org/10.1093/rheumatology/kei251 . Epub 2005 Dec 20. PMID:16368732.
doi: 10.1093/rheumatology/kei251
Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a Skin Disease. Arthritis Rheum. 2005;52(9):2873–81. https://doi.org/10.1002/art.21264 . PMID:16142730.
doi: 10.1002/art.21264
Hashkes PJ, Becker ML, Cabral DA et al. Methotrexate: new uses for an old drug. J Pediatr. 2014;164(2):231-6. https://doi.org/10.1016/j.jpeds.2013.10.029 . PMID: 24286573.
Zulian F, Tirelli F. Treatment in Juvenile Scleroderma. Curr Rheumatol Rep. 2020;22(8):45. https://doi.org/10.1007/s11926-020-00910-x . PMID: 32591919.
doi: 10.1007/s11926-020-00910-x
Zulian F, Culpo R, Sperotto, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78(8):1019–24. https://doi.org/10.1136/annrheumdis-2018-214697 . Epub 2019 Mar 2. PMID: 30826775; PMCID:PMC6691928.
doi: 10.1136/annrheumdis-2018-214697
Agazzi A, Fadanelli G, Vittadello F, et al. Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma. Pediatr Rheumatol Online J. 2018;16(1):37. https://doi.org/10.1186/s12969-018-0254-9 . PMID: 29914516; PMCID: PMC6006585.
doi: 10.1186/s12969-018-0254-9
Martini G, Murray KJ, Howell KJ et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford). 2002;41(10):1178-82. https://doi.org/10.1093/rheumatology/41.10.1178 . PMID: 12364640.
Martini G, Campus S, Raffeiner B, et al. Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases? Clin Exp Rheumatol. 2017;35(Suppl. 106(4)):211–3. Epub 2017 Sep 29. PMID: 28980909.
Lythgoe H, Baildam E, Beresford MW, et al. Tocilizumab as a potential therapeutic optionfor children with severe, refractory juvenile localized scleroderma. Rheumatology(Oxford). 2018;57(2):398–401. https://doi.org/10.1093/rheumatology/kex382 . PMID: 29077971.
doi: 10.1093/rheumatology/kex382
Zulian F, Martini G, Vallongo C et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011Jul;63(7):1998–2006. https://doi.org/10.1002/art.30264 . PMID: 21305525.
Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of Pediatric Localized Scleroderma. Front Immunol. 2019;10:908. https://doi.org/10.3389/fimmu.2019.00908 . PMID: 31114575; PMCID: PMC6503092.
doi: 10.3389/fimmu.2019.00908
Flores Quispe SKJ, Cavaliere A, Weber M, et al. Sarcopenia in juvenile localized scleroderma: new insights on deep involvement. Eur Radiol. 2020;30(7):4091–7. https://doi.org/10.1007/s00330-020-06764-2 . Epub 2020 Mar 6. PMID: 32144460.
doi: 10.1007/s00330-020-06764-2
Eutsler EP, Horton DB, Epelman M et al. Musculoskeletal MRI findings of juvenile localized scleroderma. Pediatr Radiol. 2017;47(4):442–449. doi: 10.1007/s00247-016-3765-x. Epub 2017 Jan 14. PMID: 28091699.
Schanz S, Fierlbeck G, Ulmer A, et al. Localized scleroderma: MR findings and clinical features. Radiology. 2011;260(3):817–24. https://doi.org/10.1148/radiol.11102136 . Epub 2011Jun 21. PMID: 21693661.
doi: 10.1148/radiol.11102136